Reply to: “Rifaximin and the DCA–serotonin axis in cirrhotic portal hypertension: how much of the benefit is bile-acid specific?”
Authors:
- Ke-Qi WangKWKe-Qi Wang
- Wei-Fen XieWXWei-Fen Xie
- 21 August 2026
- journal article
- Published by Elsevier in Journal of Hepatology
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Rifaximin and the DCA–serotonin axis in cirrhotic portal hypertension: how much of the benefit is bile-acid specific?Journal of Hepatology, 2026
- Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acidJournal of Hepatology, 2026
- Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the communityJournal of Hepatology, 2025
- Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal HypertensionGastroenterology, 2024
- Targeting the gut-liver axis in liver diseaseJournal of Hepatology, 2017